📢 Breaking news: The #FDA has granted traditional approval to pirtobrutinib (Jaypirca) for covalent BTKi-pretreated adult patients with R/R chronic lymphocytic #leukemia (CLL) or small lymphocytic #lymphoma (SLL). 💡 The decision, supported by the phase 3 BRUIN-CLL-321 trial, changes the drug’s previous accelerated approval to a full approval. 🔗 Read more about the approval → https://hubs.li/Q03WGRrD0 #FDAApproved #DrugDevelopment #Medicine #Oncology #Cancer
Targeted Oncology
Online Audio and Video Media
Cranbury Township, New Jersey 63,512 followers
The Community Resource in Targeted Therapies
About us
TargetedOnc.com provides content focused on next generation therapeutics and their molecular targets. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying recent and up-to-date with the future of cancer therapeutics. TargetedOnc.com focuses on the next stage of cancer development, focusing on cutting edge therapies and their biological targets. Content is organized by therapy type, target, peer-reviewed content, and conference coverage.
- Website
-
http://targetedonc.com
External link for Targeted Oncology
- Industry
- Online Audio and Video Media
- Company size
- 2-10 employees
- Headquarters
- Cranbury Township, New Jersey
- Type
- Public Company
- Specialties
- Oncology, Healthcare Communications, Healthcare, Cancer Research, Targeted Therapies, Community Oncology, Cancer, Cancer Treatment, and Oncologists
Locations
-
Primary
Get directions
2 Clarke Dr
Cranbury Township, New Jersey, US
Employees at Targeted Oncology
Updates
-
John Theurer Cancer Center at Hackensack University Medical Center is making a significant impact at the ASH Annual Meeting, presenting 65 studies that underscore our commitment to advancing blood cancer treatment. "Our teams are redefining transplantation, advancing CAR-T science, and co-leading trials testing next-generation targeted therapies and immunotherapies," says Dr. André Goy, Chair and Physician-in-Chief. We are dedicated to rapidly translating scientific breakthroughs into clinical practice for patients with blood cancers and other serious blood disorders. We look forward to connecting with our physician colleagues at #ASH25. #ASH25 #CancerCare #ClinicalTrials #Leukemia #Lymphoma #Myeloma
-
-
We hosted a dynamic Case-Based Roundtable last night in Somerville, NJ with Dr. Adam Brufsky, who walked through two real-world breast cancer cases and discussed how emerging data are shaping the use of CDK4/6 inhibitors. Don’t miss the next live discussion, sign up for text reminders to receive your invitation here: https://bit.ly/48hBowg
-
-
🤔What abstracts are you watching for at #ASH2025? Look out for the polls on our social media and follow along for ASH 2025 coverage with Targeted Oncology✔️
-
-
Which of these abstracts in heme malignancies are you most anticipating at #ASH2025?
This content isn’t available here
Access this content and more in the LinkedIn app
-
📝 Your November 2025 #FDA Roundup is here! November saw a massive wave of pivotal regulatory decisions across numerous #cancer types, shaping the future of #oncology care. 🔗 Read about the past month’s FDA approvals and other actions on our site → https://hubs.li/Q03WhQdW0
-
-
Dr. Stefania Morganti sat down with Targeted Oncology to talk about the ways MRD is being used to guide treatment decisions in early-stage breast cancer.💡 "...But the data that we generated so far retrospectively show that for patients who have MRD-positive disease, the risk of recurrence is much, much higher than for patients who remain, especially, sitting at ctDNA-negative, and not just negative at a single time point. So, we really need to design clinical trials to intervene…and see if we, by giving more or switching therapy, can improve outcomes in this patient."🌐 Read part 1 of the interview here: https://hubs.ly/Q03VHNKQ0
-